氯吡格雷联合阿司匹林对比单用阿司匹林治疗急性轻型缺血性卒中或高危短暂性脑缺血发作:系统综述与荟萃分析
结果显示,症状发作24小时内启动双联治疗可降低非致死性复发性卒中风险(RR 0.70,95%CI 0.61-0.80),但可能增加中重度颅外出血(RR 1.71,95%CI 0.92-3.20)。
要点
- 症状发作24小时内启动氯吡格雷联合阿司匹林可降低复发性卒中风险。
- 双联治疗对全因死亡率无显著影响,但可能增加中重度颅外出血。
- 建议在21天内(可能早至10天)停用双联治疗以最大化获益并最小化风险。
核心结论
- 高危TIA或轻型缺血性卒中后24小时内启动氯吡格雷联合阿司匹林双联抗血小板治疗可减少后续卒中约20/1000人群,但可能增加中重度出血约2/1000人群。
- 双联治疗的获益主要集中在随机化后10天内,21天后获益极不可能。
研究设计与样本
- 系统综述与荟萃分析,纳入随机安慰剂对照试验。
- 检索Medline、Embase、Cochrane对照试验中心注册库等数据库至2018年7月4日。
- 采用改良Cochrane偏倚风险工具评估偏倚风险,基于GRADE方法学进行分析。
主要发现
- 与单用阿司匹林相比,症状发作24小时内启动氯吡格雷联合阿司匹林降低非致死性复发性卒中风险(RR 0.70,95%CI 0.61-0.80,I²=0%,绝对风险降低1.9%,高质量证据)。
- 双联治疗对全因死亡率无显著影响(RR 1.27,95%CI 0.73-2.23,I²=0%,中等质量证据)。
- 双联治疗可能增加中重度颅外出血(RR 1.71,95%CI 0.92-3.20,I²=32%,绝对风险增加0.2%,中等质量证据)。
- 大多数卒中事件及双联与单药治疗组间发生率曲线的分离出现在随机化后10天内。
临床怎么用
- 对急性轻型缺血性卒中或高危TIA患者,可在症状发作24小时内启动氯吡格雷联合阿司匹林双联抗血小板治疗。
- 双联治疗应在21天内(可能早至10天)停用,以最大化获益并最小化出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA). DESIGN: Systematic review and meta-analysis of randomised, placebo controlled trials. DATA SOURCES: Medline, Embase, Cochrane Central Register of Controlled Trials, Cochrane Library, ClinicalTrials.gov, WHO website, PsycINFO, and grey literature up to 4 July 2018. ELIGIBILITY CRITERIA FOR SELECTING STUDIES AND METHODS: Two reviewers independently screened potentially eligible studies according to predefined selection criteria and assessed the risk of bias using a modified version of the Cochrane risk of bias tool. A third team member reviewed all final decisions, and the team resolved disagreements through discussion. When reports omitted data that were considered important, clarification and additional information was sought from the authors. The analysis was conducted in RevMan 5.3 and MAGICapp based on GRADE methodology. RESULTS: Three eligible trials involving 10 447 participants were identified. Compared with aspirin alone, dual antiplatelet therapy with clopidogrel and aspirin that was started within 24 hours of symptom onset reduced the risk of non-fatal recurrent stroke (relative risk 0.70, 95% confidence interval 0.61 to 0.80, I2=0%, absolute risk reduction 1.9%, high quality evidence), without apparent impact on all cause mortality (1.27, 0.73 to 2.23, I2=0%, moderate quality evidence) but with a likely increase in moderate or severe extracranial bleeding (1.71, 0.92 to 3.20, I2=32%, absolute risk increase 0.2%, moderate quality evidence). Most stroke events, and the separation in incidence curves between dual and single therapy arms, occurred within 10 days of randomisation; any benefit after 21 days is extremely unlikely. CONCLUSIONS: Dual antiplatelet therapy with clopidogrel and aspirin given within 24 hours after high risk TIA or minor ischaemic stroke reduces subsequent stroke by about 20 in 1000 population, with a possible increase in moderate to severe bleeding of 2 per 1000 population. Discontinuation of dual antiplatelet therapy within 21 days, and possibly as early as 10 days, of initiation is likely to maximise benefit and minimise harms.
引用
- Hao Q, Tampi M, O'Donnell M, et al. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. BMJ. 2018. PMID: 30563866. doi:10.1136/bmj.k5108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。